Correlates of lending needles/syringes among HIV-seropositive injection drug users.
about
Development of Hematopoietic Stem Cell Based Gene Therapy for HIV-1 Infection: Considerations for Proof of Concept Studies and Translation to Standard Medical PracticeHigh prevalence of syringe lending among HIV-positive people who inject drugs in Bangkok, Thailand.Secondary prevention of HIV infection: the current state of prevention for positivesWhen to start antiretroviral therapy in resource-limited settings: a human rights analysis.Predictors of sharing injection equipment by HIV-seropositive injection drug users.Social norms, social networks, and HIV risk behavior among injection drug users.Longitudinal analysis of the relationship between perceived norms and sharing injection paraphernalia.Microdevices for examining immunological responses of single cells to HIVPerceived serosorting of injection paraphernalia sharing networks among injection drug users in Baltimore, MD.Does initiation of HIV antiretroviral therapy influence patterns of syringe lending among injection drug users?All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997-2010.Asymptomatic HIV-infected individuals on antiretroviral therapy exhibit impaired lung CD4(+) T-cell responses to mycobacteria.Mortality and its predictors among antiretroviral therapy naïve HIV-infected individuals with CD4 cell count ≥350 cells/mm(3) compared to the general population: data from a population-based prospective HIV cohort in Uganda.Employment-based abstinence reinforcement following inpatient detoxification in HIV-positive opioid and/or cocaine-dependent patients.Reduced IgM levels and elevated IgG levels against oxidized low-density lipoproteins in HIV-1 infection.Is injection serosorting occurring among HIV-positive injection drug users? Comparison by injection partner's HIV statusHIV infection during limited versus combined HIV prevention programs for IDUs in New York City: the importance of transmission behaviors.Cancer screening in patients infected with HIV.Short- and long-term outcomes of HIV-infected patients admitted to the intensive care unit: impact of antiretroviral therapy and immunovirological status.Development and psychometric testing of a barriers to HIV testing scale among individuals with HIV infection in Sweden; The Barriers to HIV testing scale-Karolinska version.Patients' demographic and clinical characteristics and level of care associated with lost to follow-up and mortality in adult patients on first-line ART in Nigerian hospitals.Trends in CD4 cell count response to first-line antiretroviral treatment in HIV-positive patients from Asia, 2003-2013: TREAT Asia HIV Observational Database Low Intensity Transfer.Continuing HIV risk in New York City injection drug users: the association of syringe source and syringe sharing.ASSOCIATION BETWEEN HIV KNOWLEDGE AND RISK BEHAVIOR IN PERSONS WHO INJECT DRUGS IN THAI NGUYEN, VIETNAM.Impact of age on markers of HIV-1 diseaseRepeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies.Proteome and Protein Network Analyses of Memory T Cells Find Altered Translation and Cell Stress Signaling in Treated Human Immunodeficiency Virus Patients Exhibiting Poor CD4 Recovery.Bloodstream infections in HIV-infected patients.Changes in sexual and drug-related risk behavior following antiretroviral therapy initiation among HIV-infected injection drug users.The association of syringe type and syringe cleaning with HCV infection among IDUs in Budapest, Hungary.Hazardous alcohol consumption among young adult IDU and its association with high risk behaviors.Oral complications of HIV disease.Age and sharing of needle injection equipment in a cohort of Massachusetts injection drug users: an observational study.Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field.Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection.Late HIV presentation: epidemiology, clinical implications and management.HIV infection and atherosclerosis: evaluating the drivers of inflammation.A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience.The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients.Using TRIM5α as an HIV therapeutic: the alpha gene?
P2860
Q29036869-EE5E5F6A-C047-4CB3-A76A-452B85DD7AA5Q30375185-74A9A2DE-1FAB-4B1B-973F-325B334F549AQ30378147-210162C0-187C-49F6-807B-40DDAADCA570Q33548096-FA5CD773-589D-4225-85B5-C37F521C5858Q33822781-1390891F-528A-495D-9B42-78EAF90C3BA0Q33925922-479BE75B-C590-4FC1-9EE4-BFD10B7F381BQ33937505-156D0F60-55CF-4B62-9340-93234DD780DFQ34065197-36EE3A79-F933-4227-8573-A48717C4AE6FQ34567931-39B40678-88B5-4C55-823C-42994739A876Q34648900-B7B11FAF-05E6-49B3-9BD7-B35A3415884DQ34958573-03643777-8965-4199-868B-2255DA7CA545Q34986921-2B6F29B6-BFAF-4C29-A561-0D69D27F4353Q35085621-16D2DACC-B778-4CEC-9CCF-2C4DBD63B547Q35095930-55B9F5F1-E2D2-4B10-87C5-81F7D6BC033DQ35122438-69835BC3-A53B-4046-AF7B-042F1C7BAE5BQ35597465-E0976F31-30A4-4A52-A02F-AC57C5EC76EFQ35659939-B7800914-B028-423A-969D-E59564AD5731Q35838509-EED7E892-DDFA-41A4-A048-C8C34158C78BQ36300347-0CDA70BE-C7AD-4DF9-94DF-42D641EA465EQ36301862-B19B81A2-D1D4-47DF-8084-2C22F8ABD5F6Q36386792-B178D5C1-1AED-4C1C-B1E7-9926D264FB83Q36410265-B33F2018-0573-4125-B990-9657DBF3E8E9Q36701912-C1801A99-8E86-4C4A-8C61-B7700C14D3A5Q36763673-E2C63DDB-726C-4AA0-B6A3-0D9C01F075F4Q36763762-4F5F849F-85A7-4D62-A3E3-F52C27869B27Q36783202-EF1D0EBB-9690-420E-A95E-7BBE5AB961A7Q36900071-972C386F-EEF5-4688-9EC6-E8C6BD1EA6D0Q36913307-D0A17E3C-281F-4CE4-8DC2-9A89B69B4A39Q36919650-790FD771-A7F4-423D-AA75-C05D418FBF17Q37067677-35C98821-895A-4AEB-AF63-4600ACE54859Q37145886-34754891-8D06-461E-B4DB-1593D30BA718Q37222240-B4D17CE8-D4F8-42C8-86C7-92F3FFCFD806Q37430582-5D05DC40-923F-4386-B96C-7B885A3876B2Q37692734-FFC6754C-E5BC-4404-BEE9-700E606CBD9AQ37862747-99256D72-EECF-4677-AFA8-26950588B3B3Q37942650-77A20B1E-32C4-488D-9B36-2F1552EE864DQ38007417-11BCCA16-81A1-4CC4-BEBA-2D7BAFE600FDQ38038817-799AD58C-11F9-4C14-81C3-87BAE6E8B2B5Q38056759-CE9A080D-2385-4429-B7EB-3AE4718BB2DBQ38088406-35FB9872-8C9D-44AB-9F8F-793D327DBAE5
P2860
Correlates of lending needles/syringes among HIV-seropositive injection drug users.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Correlates of lending needles/syringes among HIV-seropositive injection drug users.
@en
Correlates of lending needles/syringes among HIV-seropositive injection drug users.
@nl
type
label
Correlates of lending needles/syringes among HIV-seropositive injection drug users.
@en
Correlates of lending needles/syringes among HIV-seropositive injection drug users.
@nl
prefLabel
Correlates of lending needles/syringes among HIV-seropositive injection drug users.
@en
Correlates of lending needles/syringes among HIV-seropositive injection drug users.
@nl
P2093
P1476
Correlates of lending needles/syringes among HIV-seropositive injection drug users.
@en
P2093
Carl A Latkin
Cynthia A Gómez
INSPIRE Study Team
Lisa R Metsch
Margaret Pereyra
Mary H Latka
Robert Malow
P356
10.1097/QAI.0B013E3181576818
P407
P478
46 Suppl 2
P577
2007-11-01T00:00:00Z